WHO approves Bavarian Nordic's mpox vaccine for adolescents
- The World Health Organisation has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17, focusing on this vulnerable age group, as reported on October 8.
- The vaccine, Jynneos, received prequalification from the WHO, which is significant for addressing global health concerns.
- Children and adolescents are particularly vulnerable to mpox, characterized by flu-like symptoms and skin lesions.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left6Leaning Right6Center2Last UpdatedBias Distribution43% Left, 43% Right
Bias Distribution
- 43% of the sources lean Left, 43% of the sources lean Right
43% Right
L 43%
14%
R 43%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage